Osteoporosis Risk Screening from Life Line Screening

No published consumer price was found on the provider's official website. Without a confirmed price, this panel cannot receive a numeric grade under the current rubric.

The single tibial signal is a reasonable narrow screen for a follow-up conversation, but the provider does not document hip or spine measurement, fracture-risk calculation, DXA confirmation, treatment monitoring, secondary-cause assessment, or an included Vitamin D test. The coverage is therefore narrower than a complete osteoporosis evaluation.

The result can inform a conversation about whether further bone evaluation is appropriate, and the provider directs higher-risk results to a physician. The broad age and annual claims exceed what the public clinical guidance establishes for routine screening, especially for men, and the product does not define its relationship to DXA diagnosis.

Three named risk categories and physician follow-up instructions provide a usable basic interpretation path. Public material does not disclose category thresholds, uncertainty, current age-specific reference data, or the precise follow-up test, while the available sample report is historical and not specific to the current tibial route.

A named tibial ultrasound route, trained personnel, and machine quality-control claims make the measurement approach identifiable. The provider does not publish device identity, analytical performance, current validation, calibration records, or a current laboratory identity, and NIH guidance limits ultrasound as a diagnostic substitute.

Life Line documents community-based in-person access, no referral requirement, preparation instructions, a typical appointment under 90 minutes, broad contiguous-state coverage, portal access, and mail delivery. The buyer still needs a location check because the assigned page warns that availability may be limited by location.

The provider publishes current general and consumer-health notices with collection, use, sharing, consent withdrawal, state rights, cookie controls, and retention principles. The notices do not give a fixed retention period for this product or explain current handling of bone images and screening records in product-specific terms.

The exact route clearly states the ultrasound site, intended audience, risk categories, and non-diagnostic follow-up boundary. Material audit gaps remain around exact price, device, current laboratory, validation, thresholds, current report format, and state-specific product availability.